



Measuring What Matters

Treasury

Submission by Medtronic Australasia Pty Ltd

January 2023

For more information on the content of this submission, please contact Kate King (kate.king@medtronic.com).

About Medtronic

Medtronic is a global leader in medical technology, services and solutions with our mission to alleviate pain, restore health, and extend life. At Medtronic we aim to transform the lives of our patients, by utilising the latest ground-breaking technology while leveraging our deep understanding of the human body.

Medtronic provides a wide range of products, therapies, and services with the aim of providing a complete continuum of care to diagnose, prevent, treat, and monitor chronic and acute conditions.

2023 marks 50 years since the commencement of our operations in Australia and our commitment to Australian patients. We are headquartered in Macquarie Park, NSW, with almost 1000 employees across the country.

Medtronic has a commitment to research and has been conducting clinical trials in Australia for over a decade, including first-in-human studies covering conditions such as coronary artery disease, end stage renal disease and hypertension.

Medtronic is an active member of the Medical Technology Association of Australia (MTAA) and supports the Industry's Code of Conduct.

Measuring What Matters

Medtronic welcomes the conversation about Measuring What Matters and considers that such an approach may assist in ensuring consistency of policy objectives across multiple interrelated portfolios. We agree that "broader measurement also allows society and governments to better evaluate the impact of decisions today on future outcomes."

We note that you are cognisant of challenges in applying the OECD Framework without recognition of the Australian context. We agree that Australia's unique context needs to be taken into account when looking at some OECD indicators.

Just as you note that GDP provides only a partial view of a community's living standards, so does the way we measure, track and treat healthcare spending across state and national jurisdictions. This is particularly the case as it relates to spending for medical technology and the healthcare outcomes that result.

At the outset we consider that part of this conversation, at least as it relates to health, needs to consider the role of value in healthcare and how we define and measure this value.

Value can come in many forms and non-economic value as well as indirect benefits should play a more substantial role in healthcare funding decisions. For example, societal value or secondary benefits of an intervention are not regularly addressed or recognised by academic Health Technology Assessment processes, for example MSAC, that determine when and how medical technology innovation is adopted. For instance, a medical technology could provide significant value delivered through innovation in procedural efficiency, acuity of care setting required, length of hospital stay, patient satisfaction,

clinical workforce safety etc, none of which significantly change the clinical outcome, but nevertheless deliver value.

We consider that Measuring What Matters has the potential to improve assessment frameworks to ensure that healthcare spending is focussed more on value delivered and outcomes that matter to patients to support improvement in the population health metric aligned with Health indicators adopted under such a framework.

We look forward to continuing to engage with you as you progress with the Measuring What Matters framework.